ImmunArray will use Quanterix's Simoa single-molecule array technology for biomarker analysis, with the potential to enrich its diagnostic panels.
As LDT developers await an FDA decision on potential new regulations and grapple with reimbursement issues, investors may be unwilling to deal with the uncertainty.
The company will develop the assays for its single-molecule array technology and incorporate the markers into multiplex assays for research use in neurology.
While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.
The firms said their test will be developed to detect levels of the tau protein that can leak into a person's bloodstream after head trauma or injury.
Three new investors joined existing investors in leading the round, which will fund desktop instrument development, international sales, and assay menu expansion.
As Quanterix continues to grow its business, quantifying proteins in single cells could drive its sales in the academic market, CEO Kevin Hrusovsky said.
The firm has signed an exclusive agreement for China with Cold Spring Biotech and a deal for Singapore, Thailand, and Malaysia with Research Instruments.
The firm has re-engineered hardware and redesigned software to improve its single-molecule array platform and has increased its multiplexing capabilities.
Using Quanterix's Simoa technology, the group developed assays to detect C. diff toxins with a high degree of sensitivity and specificity.
In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.
Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.
In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.
Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.